Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies

IF 6.9 2区 医学 Q1 HEMATOLOGY
Azin Vakilpour , Bénédicte Lefebvre , Catherine Lai , Marielle Scherrer-Crosbie
{"title":"Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies","authors":"Azin Vakilpour ,&nbsp;Bénédicte Lefebvre ,&nbsp;Catherine Lai ,&nbsp;Marielle Scherrer-Crosbie","doi":"10.1016/j.blre.2023.101166","DOIUrl":null,"url":null,"abstract":"<div><p><span>Cancer survivors are at significant risk of cardiovascular (CV) morbidity and mortality; patients with hematologic malignancies<span> have a higher rate of death due to heart failure compared to all other cancer subtypes. The majority of conventional hematologic cancer treatments is associated with increased risk of acute and long-term CV toxicity<span><span>. The incidence of cancer therapy induced CV toxicity depends on the combination of </span>patient characteristics<span> and on the type, dose, and duration of the therapy. Early diagnosis of CV toxicity, appropriate referral, more specific cardiac monitoring follow-up and timely interventions in target patients can decrease the risk of CV adverse events, the interruption of oncological therapy, and improve the patient's prognosis. Herein, we summarize the </span></span></span></span>CV effects of conventional treatments used in hematologic malignancies with a focus on definitions and incidence of the most common CV toxicities, guideline recommended early detection approaches, and preventive strategies before and during cancer treatments.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101166"},"PeriodicalIF":6.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23001364","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer survivors are at significant risk of cardiovascular (CV) morbidity and mortality; patients with hematologic malignancies have a higher rate of death due to heart failure compared to all other cancer subtypes. The majority of conventional hematologic cancer treatments is associated with increased risk of acute and long-term CV toxicity. The incidence of cancer therapy induced CV toxicity depends on the combination of patient characteristics and on the type, dose, and duration of the therapy. Early diagnosis of CV toxicity, appropriate referral, more specific cardiac monitoring follow-up and timely interventions in target patients can decrease the risk of CV adverse events, the interruption of oncological therapy, and improve the patient's prognosis. Herein, we summarize the CV effects of conventional treatments used in hematologic malignancies with a focus on definitions and incidence of the most common CV toxicities, guideline recommended early detection approaches, and preventive strategies before and during cancer treatments.

心碎者检测和预防血液恶性肿瘤的心脏毒性
癌症幸存者面临心血管疾病(CV)发病率和死亡率的巨大风险;与所有其他癌症亚型相比,血液系统恶性肿瘤患者因心力衰竭而死亡的比例更高。大多数常规血液肿瘤治疗都会增加急性和长期心血管毒性的风险。癌症治疗诱发心血管毒性的发生率取决于患者的综合特征以及治疗的类型、剂量和持续时间。对目标患者进行心血管毒性的早期诊断、适当的转诊、更具体的心脏监测随访和及时的干预,可以降低心血管不良事件的风险,减少肿瘤治疗的中断,并改善患者的预后。在此,我们总结了血液系统恶性肿瘤常规治疗对心血管的影响,重点介绍了最常见心血管毒性的定义和发生率、指南推荐的早期检测方法以及癌症治疗前和治疗过程中的预防策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信